ELIQUENT Experts Discuss Product Quality & Patient Safety

Greenleaf regulatory compliance experts Donald Ashley, Kalah Auchincloss, and Elizabeth Oestreich co-authored a piece in the most recent issue of Food and Drug Law Institute (FDLI)’s Food and Drug Law Journal entitled Implications of Recent Third Circuit Court of Appeals Decision for FDA Drug Approval Framework. Their piece focuses on the potential drawbacks to the decision in United States v. Vepuri as pertaining to product quality, patient safety, and other issues.

Read the full FDLI article.